ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2308건의 자료가 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2231 | Active, not recruiting | A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults | COVID-19 | Biological: EuCorVac-19 Biological: ChAdOx1 nCoV-19 |
Phase 3 | EuBiologics Co.,Ltd | INDUSTRY | 2600 | All | 18 Years | Trial site, Manila, Philippines |
| 2230 | Completed | A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19. | SARS-CoV-2 Acute Respiratory Disease | Biological: COVID-19 Vaccine 40 ug/dose | Phase 3 | Hipra Scientific, S.L.U | INDUSTRY | 2646 | All | 16 Years | Hospital de Niguarda, Milano, Italy Hospital Germans Trias I Pujol, Badalona, Barcelona, Spain Hospital de Mollet, Mollet Del Valles, Barcelona, Spain Hospital Principe de Asturias, Meco, Madrid, Spain Hospital HM Puerta del Sur, Mostoles, Madrid, Spain Hospital de Cruces, Barakaldo, Vizcaya, Spain Hospital HM Delfos, Barcelona, Spain Hospital Quironsalud Barcelona, Barcelona, Spain Hospital Vall Hebron, Barcelona, Spain Hospital Clinic de Barcelona, Barcelona, Spain Hospital Universitari Dr. Josep Trueta, Girona, Spain Hospital Gregorio Maranon, Madrid, Spain Hospital Universitario La Paz, Madrid, Spain Hospital HM Sanchinarro, Madrid, Spain Hospital Quironsalud Madrid, Madrid, Spain Hospital HM Monteprincipe, Madrid, Spain Hospital Regional Universitario de Malaga, Malaga, Spain Hospital Clinico de Valencia, Valencia, Spain |
| 2229 | Completed | A Phase III, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TD0069 Capsule for Patients With Mild to Moderate COVID-19 | COVID-19 | Drug: TD0069 hard capsule Drug: TD0069 Placebo |
Phase 3 | Sao Thai Duong Joint Stock Company, CLINICAL RESEARCH VIET NAM SKILL TRAINING AND CONSULTING COMPANY LIMITED | INDUSTRY | 573 | All | 18 Years ~ 65 Years | Traditional Medicine Institute in Ho Chi Minh City, Ho Chi Minh City, Ho Chi Minh, Vietnam Hanoi Hospital of Traditional Medicine, Ha Noi, Vietnam |
| 2228 | Completed | A Phase IV Vaccine Study Under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2 (COVID-19) Vaccines. | SARS CoV 2 Infection | Biological: Johnson & Johnson | Phase 4 | Jens D Lundgren, MD, Ministry of the Interior and Health, Denmark | OTHER | 25 | All | 18 Years | Aarhus Universitetshospital, Skejby, Aarhus, Aarhus N, Denmark Aalborg Universitetshospital Syd, Aalborg, Denmark Hvidovre Hospital, Hvidovre, Denmark Odense Universitetshospital, Odense, Denmark Sjællandsuniversitetshospital, Roskilde, Denmark |
| 2227 | Completed | A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine | COVID-19 Pandemic | Biological: SCTV01E Biological: Placebo (normal saline) |
Phase 2 | Sinocelltech Ltd. | INDUSTRY | 518 | All | 3 Years ~ 120 Years | Lianshui County Center for Disease Control and Prevention, Lianshui, Jiangsu, China Jiangsu Center for Disease Control and Prevention, Nanjing, Jiangsu, China Taizhou Vaccine Clinical Research Center, Taizhou, Jiangsu, China Dazhu County Center for Disease Control and Prevention, Dazhou, Si Chuan, China |
| 2226 | Recruiting | A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine | SARS-CoV-2 Infection | Biological: COVID-19 mRNA Vaccine (ZSVG-02-O) Biological: COVID-19 mRNA Vaccine (ZSVG-02-O) Biological: COVID-19 Vaccine (Vero Cell) ,Inactivated |
Phase 2 | CNBG-Virogin Biotech (Shanghai) Ltd. | INDUSTRY | 980 | All | 18 Years ~ 99 Years | Dengfeng Centre for Disease Control and Prevention and Control, Dengfeng, Henan, China Henan Provincial Centre for Disease Control and Prevention, Zhengzhou, Henan, China |
| 2225 | Recruiting | A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection | COVID-19 | Drug: Experimental: Primary Cohort Other: Placebo Comparator: Primary Cohort - Placebo |
Phase 4 | University of Chicago | OTHER | 280 | All | 18 Years | University of Chicago, Chicago, Illinois, United States |
